Searched for: in-biosketch:true
person:katzj25
Trends and Outcomes in Cardiac Arrest Among Heart Failure Admissions
Chouairi, Fouad; Miller, P Elliott; Loriaux, Daniel B; Katz, Jason N; Sen, Sounok; Ahmad, Tariq; Fudim, Marat
There is limited large, national data investigating the prevalence, characteristics, and outcomes of cardiac arrest (CA) in patients hospitalized for heart failure (HF). The goal of this study was to examine the characteristics, trends, and outcomes of HF hospitalizations complicated by in-hospital CA. We used the National Inpatient Sample to identify all primary HF admissions from 2016 to 2019. Cohorts were built based on the presence of a codiagnosis of CA. Diagnoses were identified using International Classification of Diseases, Tenth Revision, Clinical Modification codes. Associations with CA were then analyzed using multivariate logistic regression. We identified a total of 4,905,564 HF admissions, 56,170 (1.1%) of which had CA. Hospitalizations complicated by CA were significantly more likely to be male, to have coronary artery disease, renal disease, and less likely to be White (p <0.001, all). Age <65 (odds ratio [OR] 1.18, p <0.001), renal disease (OR 2.41, p <0.001), and coronary artery disease (OR 1.26, p <0.001) had higher odds of CA while female gender (OR 0.84, confidence interval [CI] 0.83 to 0.86, p <0.001) or HFpEF (OR 0.49, CI 0.48 to 0.50, p <0.001) had lower odds of CA. Patients with CA had higher inpatient mortality (CA 54.2% vs no CA 2.1%, p <0.001), which persisted after multivariate adjustment (OR 64.8, CI 63.5 to 66.0, p <0.001). CA occurs in >1 in 1,000 HF hospitalizations and remains a prominent and serious event associated with a high mortality. Further research is needed to examine long-term outcomes and mechanical circulatory support utilization with more granularity in HF patients with in-hospital CA.
PMID: 36889986
ISSN: 1879-1913
CID: 5788312
Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial [Comment]
Mehra, Mandeep R; Netuka, Ivan; Uriel, Nir; Katz, Jason N; Pagani, Francis D; Jorde, Ulrich P; Gustafsson, Finn; Connors, Jean M; Ivak, Peter; Cowger, Jennifer; Ransom, John; Bansal, Aditya; Takeda, Koji; Agarwal, Richa; Byku, Mirnela; Givertz, Michael M; Bitar, Abbas; Hall, Shelley; Zimpfer, Daniel; Vega, J David; Kanwar, Manreet K; Saeed, Omar; Goldstein, Daniel J; Cogswell, Rebecca; Sheikh, Farooq H; Danter, Matthew; Pya, Yuriy; Phancao, Anita; Henderson, John; Crandall, Daniel L; Sundareswaran, Kartik; Soltesz, Edward; Estep, Jerry D; ,
IMPORTANCE:Left ventricular assist devices (LVADs) enhance quality and duration of life in advanced heart failure. The burden of nonsurgical bleeding events is a leading morbidity. Aspirin as an antiplatelet agent is mandated along with vitamin K antagonists (VKAs) with continuous-flow LVADs without conclusive evidence of efficacy and safety. OBJECTIVE:To determine whether excluding aspirin as part of the antithrombotic regimen with a fully magnetically levitated LVAD is safe and decreases bleeding. DESIGN, SETTING, AND PARTICIPANTS:This international, randomized, double-blind, placebo-controlled study of aspirin (100 mg/d) vs placebo with VKA therapy in patients with advanced heart failure with an LVAD was conducted across 51 centers with expertise in treating patients with advanced heart failure across 9 countries. The randomized population included 628 patients with advanced heart failure implanted with a fully magnetically levitated LVAD (314 in the placebo group and 314 in the aspirin group), of whom 296 patients in the placebo group and 293 in the aspirin group were in the primary analysis population, which informed the primary end point analysis. The study enrolled patients from July 2020 to September 2022; median follow-up was 14 months. INTERVENTION:Patients were randomized in a 1:1 ratio to receive aspirin (100 mg/d) or placebo in addition to an antithrombotic regimen. MAIN OUTCOMES AND MEASURES:The composite primary end point, assessed for noninferiority (-10% margin) of placebo, was survival free of a major nonsurgical (>14 days after implant) hemocompatibility-related adverse events (including stroke, pump thrombosis, major bleeding, or arterial peripheral thromboembolism) at 12 months. The principal secondary end point was nonsurgical bleeding events. RESULTS:Of the 589 analyzed patients, 77% were men; one-third were Black and 61% were White. More patients were alive and free of hemocompatibility events at 12 months in the placebo group (74%) vs those taking aspirin (68%). Noninferiority of placebo was demonstrated (absolute between-group difference, 6.0% improvement in event-free survival with placebo [lower 1-sided 97.5% CI, -1.6%]; P < .001). Aspirin avoidance was associated with reduced nonsurgical bleeding events (relative risk, 0.66 [95% confidence limit, 0.51-0.85]; P = .002) with no increase in stroke or other thromboembolic events, a finding consistent among diverse subgroups of patient characteristics. CONCLUSIONS AND RELEVANCE:In patients with advanced heart failure treated with a fully magnetically levitated LVAD, avoidance of aspirin as part of an antithrombotic regimen, which includes VKA, is not inferior to a regimen containing aspirin, does not increase thromboembolism risk, and is associated with a reduction in bleeding events. TRIAL REGISTRATION:ClinicalTrials.gov Identifier: NCT04069156.
PMID: 37950897
ISSN: 1538-3598
CID: 5788382
Preparing cardiovascular patients for the operative theatre
Loriaux, Daniel B; McCartney, Sharon; Rampersad, Penelope; Bryner, Benjamin; Katz, Jason N
PMID: 36746806
ISSN: 2048-8734
CID: 5788302
The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischaemic heart disease
Price, Susanna; Kaski, Juan Carlos; Al-Lamee, Rasha; Boden, William E; Huber, Kurt; Katz, Jason N; Krychtiuk, Konstantin
PMID: 36587938
ISSN: 1522-9645
CID: 5788292
Trajectories of Palliative Care Needs in the ICU and Long-Term Psychological Distress Symptoms
Cox, Christopher E; Gu, Jessie; Ashana, Deepshikha Charan; Pratt, Elias H; Haines, Krista; Ma, Jessica; Olsen, Maren K; Parish, Alice; Casarett, David; Al-Hegelan, Mashael S; Naglee, Colleen; Katz, Jason N; O'Keefe, Yasmin Ali; Harrison, Robert W; Riley, Isaretta L; Bermejo, Santos; Dempsey, Katelyn; Johnson, Kimberly S; Docherty, Sharron L
OBJECTIVES:While palliative care needs are assumed to improve during ICU care, few empiric data exist on need trajectories or their impact on long-term outcomes. We aimed to describe trajectories of palliative care needs during ICU care and to determine if changes in needs over 1 week was associated with similar changes in psychological distress symptoms at 3 months. DESIGN:Prospective cohort study. SETTING:Six adult medical and surgical ICUs. PARTICIPANTS:Patients receiving mechanical ventilation for greater than or equal to 2 days and their family members. MEASUREMENTS AND MAIN RESULTS:The primary outcome was the 13-item Needs at the End-of-Life Screening Tool (NEST; total score range 0-130) completed by family members at baseline, 3, and 7 days. The Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and Post-Traumatic Stress Scale (PTSS) were completed at baseline and 3 months. General linear models were used to estimate differences in distress symptoms by change in need (NEST improvement ≥ 10 points or not). One-hundred fifty-nine family members participated (median age, 54.0 yr [interquartile range (IQR), 44.0-63.0 yr], 125 [78.6%] female, 54 [34.0%] African American). At 7 days, 53 (33%) a serious level of overall need and 35 (22%) ranked greater than or equal to 1 individual need at the highest severity level. NEST scores improved greater than or equal to 10 points in only 47 (30%). Median NEST scores were 22 (IQR, 12-40) at baseline and 19 (IQR, 9-37) at 7 days (change, -2.0; IQR, -11.0 to 5.0; p = 0.12). There were no differences in PHQ-9, GAD-7, or PTSS change scores by change in NEST score (all p > 0.15). CONCLUSIONS:Serious palliative care needs were common and persistent among families during ICU care. Improvement in needs was not associated with less psychological distress at 3 months. Serious needs may be commonly underrecognized in current practice.
PMID: 36326263
ISSN: 1530-0293
CID: 5782452
Association of Angiopoetin-2 and TNF-α With Bleeding During Left Ventricular Assist Device Support: Analysis From the PREVENT Biorepository
Kim, Gene; Sayer, Gabriel; Ransom, John; Keebler, Mary; Katz, Jason; Kilic, Ahmet; Lindenfeld, JoAnn; Egnaczyk, Gregory; Shah, Palak; Brieke, Andreas; Walenga, Jeanine; Crandall, Daniel; Farrar, David J; Sundareswaran, Kartik; Uriel, Nir
The purpose of this study was to describe the changes in plasma levels of angiogenic and inflammatory biomarkers, specifically Ang-2 and TNF-α, in patients receiving HeartMate II (HMII) left ventricular assist device (LVAD) and correlate them with nonsurgical bleeding. It has been shown that angiopoietin-2 (Ang-2) and tissue necrosis factor-α (TNF-α) may be linked to bleeding in LVAD patients. This study utilized biobanked samples prospectively collected from the PREVENT study, a prospective, multicenter, single-arm, nonrandomized study of patients implanted with HMII. Paired serum samples were obtained in 140 patients before implantation and at 90 days postimplantation. Baseline demographics were as follows: age 57 ± 13 years, 41% had ischemic etiology, 82% male, and 75% destination therapy indication. In the 17 patients with baseline elevation of both TNF-α and Ang-2, 10 (60%) experienced a significant bleeding event within 180 days postimplant compared with 37 of 98 (38%) patients with Ang-2 and TNF-α below the mean ( p = 0.02). The hazard ratio for a bleeding event was 2.3 (95% CI: 1.2-4.6) in patients with elevated levels of both TNF-α and Ang-2. In the PREVENT multicenter study, patients with elevations in serum Angiopoietin-2 and TNF-α at baseline before LVAD implantation demonstrated increased bleeding events after LVAD implantation.
PMID: 37134003
ISSN: 1538-943x
CID: 5782802
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M; Berg, David D; Bohula, Erin A; Baird-Zars, Vivian M; Barnett, Christopher F; Barsness, Gregory W; Chaudhry, Sunit-Preet; Daniels, Lori B; van Diepen, Sean; Ghafghazi, Shahab; Goldfarb, Michael J; Jentzer, Jacob C; Katz, Jason N; Kenigsberg, Benjamin B; Lawler, Patrick R; Miller, P Elliott; Papolos, Alexander I; Park, Jeong-Gun; Potter, Brian J; Prasad, Rajnish; Singam, N Sarma V; Sinha, Shashank S; Solomon, Michael A; Teuteberg, Jeffrey J; Morrow, David A; ,
BACKGROUND:Algorithmic application of the 2019 Society of Cardiovascular Angiography and Intervention (SCAI) shock stages effectively stratifies mortality risk for patients with cardiogenic shock. However, clinician assessment of SCAI staging may differ. Moreover, the implications of the 2022 SCAI criteria update remain incompletely defined. METHODS:The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units (CICUs). Between 2019 and 2021, participating centers (n=32) contributed at least a 2-month snapshot of consecutive medical CICU admissions. In-hospital mortality was assessed across 3 separate staging methods: clinician assessment, Critical Care Cardiology Trials Network algorithmic application of the 2019 SCAI criteria, and a revision of the Critical Care Cardiology Trials Network application using the 2022 SCAI criteria. RESULTS: CONCLUSIONS:Both clinician and algorithm-based application of the 2019 SCAI stages identify a stepwise gradient of mortality risk, although clinician-staging may better allocate higher risk patients into advanced SCAI stages. Updated algorithmic staging using the 2022 SCAI criteria and vasoactive-inotropic score further refines risk stratification.
PMCID:9851990
PMID: 36458542
ISSN: 1941-3297
CID: 5783142
Advanced Heart Failure in the Cardiac Intensive Care Unit: A Community-Based Study [Letter]
Jentzer, Jacob C; Redfield, Margaret M; Killian, Jill; Katz, Jason N; Roger, Veronique L; Dunlay, Shannon M
PMCID:10308359
PMID: 36754533
ISSN: 2213-1787
CID: 5783152
Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study
Jeske, Walter; Ransom, John; Katz, Jason N; Kilic, Ahmet; Lindenfeld, Joann; Egnaczyk, Gregory; Shah, Palak; Brieke, Andreas; Uriel, Nir; Crandall, Daniel; Farrar, David J; Walenga, Jeanine M
The aim of this investigation was to characterize the hemostatic status of heart failure patients with implanted left ventricular assist devices (LVADs) to propose a mechanism associated with bleeding. Patients (n = 300) from 23 US hospitals were enrolled in the PREVENtion of HeartMate II Pump Thrombosis through Clinical Management (PREVENT) study. A biobank was established with serum and plasma samples prospectively collected from a cohort of 175 patients preimplant baseline (BL) and 3 months (3M) postimplant. Outcomes were collected for 6 months. Thrombin (prothrombin fragment 1.2 [F1.2], functional thrombin generation [TG]) and fibrinolytic activity (D-dimer, plasminogen activator inhibitor-1 [PAI-1]), but not contact activation (complement C5a), were elevated in heart failure patients at BL. F1.2, TG, and PAI-1 levels decreased 3M after LVAD implantation ( p < 0.01) but did not revert to normal in all patients; conversely, D-dimer increased BL to 3M ( p < 0.01). Compared with patients without events, thrombin activity (F1.2) was increased in patients with late bleeding (3-4 months postimplant) ( p = 0.06) and in those with late gastrointestinal (GI) bleeding ( p = 0.01). Patients with 3M F1.2 levels above the cohort mean had a higher incidence of bleeding ( p < 0.001) and GI bleeding ( p < 0.001) compared with those with below mean F1.2. Patients experiencing multiple bleeding events were more likely to have 3M F1.2 greater than the cohort mean. Despite anticoagulation with aspirin and warfarin, LVAD implanted patients exhibit hemostatic activation. Excess thrombin formation, particularly shown by increased F1.2, was demonstrated in association with bleeding in LVAD implanted patients.
PMID: 36731068
ISSN: 1538-943x
CID: 5782462
Family Engagement in the Adult Cardiac Intensive Care Unit: A Survey of Family Engagement Practices in the Cardiac Critical Care Trials Network
Goldfarb, Michael; Alviar, Carlos; Berg, David; Katz, Jason; Lee, Ran; Liu, Shuangbo; Maitz, Theresa; Padkins, Mitchell; Prasad, Rajnish; Roswell, Robert; Shah, Kevin; Thompson, Andrea; van Diepen, Sean; Zakaria, Sammy; Morrow, David
BACKGROUND:Cardiovascular and critical care professional societies recommend incorporating family engagement practices into routine clinical care. However, little is known about current family engagement practices in contemporary cardiac intensive care units (CICUs). METHODS:We implemented a validated 12-item family engagement practice survey among site investigators participating in the Critical Care Cardiology Trials Network, a collaborative network of CICUs in North America. The survey includes 9 items assessing specific engagement practices, 1 item about other family-centered care practices, and 2 open-ended questions on strategies and barriers concerning family engagement practice. We developed an engagement practice score by assigning 1 point for each family engagement practice partially or fully adopted at each site (max score 9). We assessed for relationships between the engagement practice score and CICU demographics. RESULTS:All sites (N=39; 100%) completed the survey. The most common family engagement practices were open visitation (95%), information and support to families (85%), structured care conferences (n=82%), and family participation in rounds (77%). The median engagement practice score was 5 (interquartile range, 4). There were no differences in engagement practice scores by geographic region or CICU type. The most commonly used strategies to promote family engagement were family presence during rounds (41%), communication (28%), and family meetings (28%). The most common barriers to family engagement were COVID-related visitation policies (38%) and resource limitations (13%). CONCLUSIONS:Family engagement practices are routinely performed in many CICUs; however, considerable variability exists. There is a need for strategies to address the variability of family engagement practices in CICUs.
PMCID:10530193
PMID: 37539538
ISSN: 1941-7705
CID: 5735002